RS68236B1 - CO-CRYSTALS, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT INCLUDING THE SAME - Google Patents

CO-CRYSTALS, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT INCLUDING THE SAME

Info

Publication number
RS68236B1
RS68236B1 RS20260702A RSP20260702A RS68236B1 RS 68236 B1 RS68236 B1 RS 68236B1 RS 20260702 A RS20260702 A RS 20260702A RS P20260702 A RSP20260702 A RS P20260702A RS 68236 B1 RS68236 B1 RS 68236B1
Authority
RS
Serbia
Prior art keywords
compound
theta
degrees
pharmaceutical composition
cancer
Prior art date
Application number
RS20260702A
Other languages
English (en)
Serbian (sr)
Inventor
Benjamin S Lane
Chong-Hui Gu
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of RS68236B1 publication Critical patent/RS68236B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20260702A 2017-11-02 2018-11-02 CO-CRYSTALS, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT INCLUDING THE SAME RS68236B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
EP18812419.2A EP3704101B1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Publications (1)

Publication Number Publication Date
RS68236B1 true RS68236B1 (en) 2026-07-31

Family

ID=64572453

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20260702A RS68236B1 (en) 2017-11-02 2018-11-02 CO-CRYSTALS, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT INCLUDING THE SAME

Country Status (25)

Country Link
US (3) US11345677B2 (enExample)
EP (1) EP3704101B1 (enExample)
JP (3) JP7335877B2 (enExample)
KR (1) KR102731624B1 (enExample)
CN (2) CN118359585A (enExample)
AU (3) AU2018360827B2 (enExample)
CA (1) CA3081535A1 (enExample)
DK (1) DK3704101T3 (enExample)
EA (1) EA202091112A1 (enExample)
ES (1) ES3075257T3 (enExample)
FI (1) FI3704101T3 (enExample)
HR (1) HRP20260783T1 (enExample)
IL (2) IL274123B2 (enExample)
LT (1) LT3704101T (enExample)
MA (1) MA50526B1 (enExample)
MX (2) MX2020004513A (enExample)
PH (1) PH12020550462A1 (enExample)
PT (1) PT3704101T (enExample)
RS (1) RS68236B1 (enExample)
SG (1) SG11202003612VA (enExample)
SI (1) SI3704101T1 (enExample)
SM (1) SMT202600262T1 (enExample)
TW (2) TWI796377B (enExample)
UA (1) UA127380C2 (enExample)
WO (1) WO2019090059A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
TW202227446A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 有機化合物之固態形式
US20230346789A1 (en) * 2022-03-31 2023-11-02 Msd International Gmbh Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
CN121843929A (zh) * 2023-09-18 2026-04-10 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
US20250257050A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013010564B1 (pt) * 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
MX2020004513A (es) 2020-09-17
BR112020008598A2 (pt) 2021-01-26
EP3704101B1 (en) 2026-05-06
CN111527076A (zh) 2020-08-11
IL274123B1 (en) 2023-09-01
IL305426B1 (en) 2024-06-01
MX2022014792A (es) 2023-01-16
JP7335877B2 (ja) 2023-08-30
HRP20260783T1 (hr) 2026-08-14
TWI796377B (zh) 2023-03-21
AU2026205552A1 (en) 2026-07-30
EP3704101A1 (en) 2020-09-09
KR102731624B1 (ko) 2024-11-19
US12679820B2 (en) 2026-07-14
CA3081535A1 (en) 2019-05-09
PT3704101T (pt) 2026-06-24
US11345677B2 (en) 2022-05-31
US20220363661A1 (en) 2022-11-17
CN111527076B (zh) 2024-03-12
FI3704101T3 (fi) 2026-06-12
UA127380C2 (uk) 2023-08-02
US11851417B2 (en) 2023-12-26
IL274123B2 (en) 2024-01-01
TW202337885A (zh) 2023-10-01
MA50526B1 (fr) 2026-06-30
AU2018360827A1 (en) 2020-05-14
JP2021501766A (ja) 2021-01-21
ES3075257T3 (en) 2026-07-29
IL305426A (en) 2023-10-01
SG11202003612VA (en) 2020-05-28
CN118359585A (zh) 2024-07-19
MA50526A (fr) 2020-09-09
JP2023093666A (ja) 2023-07-04
EA202091112A1 (ru) 2020-07-23
KR20240166601A (ko) 2024-11-26
US20240343705A1 (en) 2024-10-17
PH12020550462A1 (en) 2021-03-22
IL305426B2 (en) 2024-10-01
WO2019090059A1 (en) 2019-05-09
IL274123A (en) 2020-06-30
LT3704101T (lt) 2026-06-25
JP7780576B2 (ja) 2025-12-04
TW201930285A (zh) 2019-08-01
DK3704101T3 (da) 2026-06-15
AU2024203186A1 (en) 2024-05-30
JP2024113028A (ja) 2024-08-21
SI3704101T1 (sl) 2026-07-31
US20210198234A1 (en) 2021-07-01
JP7499377B2 (ja) 2024-06-13
AU2024203186B2 (en) 2026-04-16
SMT202600262T1 (it) 2026-07-16
AU2018360827B2 (en) 2024-02-22
TWI839131B (zh) 2024-04-11
KR20200095480A (ko) 2020-08-10